Prediction of in vivo nonlinear first-pass hepatic metabolism of YM796 from in vitro metabolic data

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 1, 1998, Pages 122-127

  Iwatsubo, Takafumi ^a   Hisaka, Akihiro ^b   Suzuki, Hiroshi ^c   Sugiyama, Yuichi ^c  

^a ASTELLAS PHARMA INC   (Japan)

^b BANYU PHARMACEUTICAL CO LTD   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,8 DIMETHYL 3 METHYLENE 1 OXA 8 AZASPIRO[4.5]DECANE; UNCLASSIFIED DRUG;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; FIRST PASS EFFECT; HUMAN; HUMAN CELL; LIVER METABOLISM; LIVER MICROSOME; METABOLIC CLEARANCE RATE; NONHUMAN; ORAL DRUG ADMINISTRATION; PORTAL VEIN; PRIORITY JOURNAL; RAT;

ABSORPTION; ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER; MALE; RATS; SPIRO COMPOUNDS;

EID: 0031870866     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bischoff KB, Dedrick RL, Zaharko DS and Longstreth JA (1971) Methotrexate pharmacokinetics. J Pharm Sci 60:1128-1133.
2. Dedrick RL, Forester DD, Cannon JN, ElDareen SM and Mellett LB (1973) Pharmacokinetics of 1-β-D-arabinofuranosylcytosine (Ara-C) deamination in several species. Biochem Pharmacol 22:2405-2417.
3. Hisaka A, Nakamura T and Sugiyama Y (1994) Analysis of drug disposition in the liver by the nonlinear dispersion model. II: Comparison among the well-stirred, parallel-tube and dispersion models, Proceedings of the 9th Annual Meeting of the Japanese Society for the Study of Xenobiotics (Yata N ed.) pp S264, Komiyama, Hiroshima, Japan.
4. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
5. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA and Sugiyama Y (1997a) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171.
6. Iwatsubo T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Yokoi T, Kamataki T and Sugiyama Y (1997b) Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. J Pharmacol Exp Ther 282:909-919.
7. Iwatsubo T, Suzuki H and Sugiyama Y (1997c) Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. J Pharmacol Exp Ther 283:462-469.
8. Ludden TM (1991) Nonlinear pharmacokinetics: Clinical implications. Clin Pharmacokinet 20:429-446.
9. Montandon B, Roberts RJ and Fischer LJ (1975) Computer simulation of sulfobromophthalein kinetics in the rat using flow-limited models with extrapolation to man. J Pharmacokinet Biopharm 3:277-290.
10. Oberle RL, Chen T-S, Lloyd C, Barnett JL, Owyang C, Meyer J and Amidon GL (1990) The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology 99:1275-1282.
11. Rane A, Wilkinson GR and Shand DG (1977) Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther 200:420-424.
12. Roberts MS and Rowland M (1986) Correlation between in vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: Analysis with a dispersion model. J Pharm Pharmacol 38:177-181.
13. Sugiyama Y, Sawada Y, Iga T and Hanano M (1988) Xenobiotic metabolism and disposition, Proceedings of the 2nd International ISSX Meeting (Kato R, Estabrook RW and Cayen MN eds) pp 225-235, Taylor & Francis, London.
14. Wilkinson GR (1987) Clearance approaches in pharmacology. Pharmacol Rev 39:1-47.